Minoxidil for Hair Regrowth — Skin & Hair
Vasodilator FDA-approved OTC for androgenetic alopecia, available topically and increasingly used orally at low doses.
Overview
Minoxidil is a potassium channel opener and vasodilator originally developed as an oral antihypertensive. Its hair growth properties were discovered as a side effect (hypertrichosis) in patients treated for severe hypertension. Topical minoxidil (Rogaine) was the first FDA-approved treatment for androgenetic alopecia (1988 for men, 1991 for women). It promotes hair growth through multiple mechanisms: opening ATP-sensitive potassium channels in dermal papilla cells, stimulating vascular endothelial growth factor (VEGF) production, prolonging the anagen phase of the hair cycle, and increasing follicular size. Topical formulations (2% and 5% solutions/foam) are available OTC. Low-dose oral minoxidil (LDOM, 0.625-5 mg daily) has gained significant traction since 2020, with retrospective studies and small RCTs suggesting superior efficacy and convenience compared to topical application. Oral minoxidil at hair-loss doses (1.25-2.5 mg) is much lower than the antihypertensive dose (10-40 mg). Minoxidil does not address the androgen-mediated component of hair loss and is often combined with finasteride or dutasteride for comprehensive management.
Indications
- FDA-approved OTC: Male androgenetic alopecia (2% and 5% topical)
- FDA-approved OTC: Female androgenetic alopecia (2% topical, 5% foam)
- Off-label: Low-dose oral minoxidil for hair loss
- FDA-approved: Severe hypertension refractory to other agents (oral, 10-40 mg — Loniten)
Mechanism of Action
Opens ATP-sensitive potassium channels in dermal papilla cells, causing cell membrane hyperpolarization and enhanced cellular activity
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Minoxidil 5% solution | 1 mL | Twice daily to scalp | FDA-approved for men; apply to dry scalp |
| Minoxidil 5% foam | Half capful | Once daily | Foam preferred — no propylene glycol, less irritation |
| Minoxidil 2% solution | 1 mL | Twice daily | FDA-approved for women; lower hypertrichosis risk |
| Minoxidil | 2.5 mg | Once daily | Off-label low-dose oral; most common dose for hair loss |
| Minoxidil | 1.25 mg | Once daily | Conservative oral starting dose |
Evidence Grade
GRADE A
Safety & Contraindications
- Topical: scalp irritation, pruritus, flaking — especially with propylene glycol solutions
- Topical: Unwanted facial hair growth (hypertrichosis) in women, especially with 5% formulation
- Oral (low-dose): Peripheral edema, tachycardia, fluid retention possible
- Oral: Pericardial effusion (rare, typically at higher antihypertensive doses)
- Oral: Hypertrichosis (expected and dose-dependent)
- Initial telogen effluvium (increased shedding) common in first 4-8 weeks — temporary
- Hair growth is dependent on continued use — cessation leads to shedding within 3-6 months
- Topical minoxidil is toxic to cats